DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies

Eric K. Rowinsky, Thomas R. Johnson, Charles E. Geyer C.E., Lisa A. Hammond, Gail G. Eckhardt, Ronald Drengler, Leslie Smetzer, John Coyle, Jinee Rizzo, Garry Schwartz, Anthony Tolcher, Daniel D. Von Hoff, Robert L. De Jager